QuickView: iDEAL study misses primary endpoint
Top-line data from the iDEAL Phase II study with iCo-007 in diabetic macular edema (DME) did not show a benefit in visual acuity (VA) after eight months, either alone or in combination with Lucentis or laser photocoagulation (LP). Full 12-month data are due in Q414, but the ~80% share price decline on the results, leading to a negative EV, suggests low investor expectations for a turnaround or further development of iCo-007.iCo Therapeutics is a biotechnology company principally focused on the identification, development and commercilization of drug candidates with a clinical history and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Co. has in-licensed three assets: iCo-007; iCo-008 and the Oral AmpB Delivery System.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.